Company news
Formosa Pharmaceuticals, Inc. news in 2025
Formosa Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.
Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
December 3, 2025
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
June 9, 2025
Decks in 2025
- 法人說明會 (Investor Conference) 2025
Conference · 43 slides · Jun 30, 2025
- Investor's Meeting (June 2025)
Conference · 43 slides · Jun 30, 2025